Vaxxinity, Inc.
🇺🇸United States
AC Immune's stock jumps after Parkinson's therapy shows signs of benefit
AC Immune's stock surged 26.9% after Phase II VacSYn trial data showed all patients responded to its Parkinson's disease vaccine-like immunotherapy, ACI-7104.056, targeting alpha-synuclein.
© Copyright 2024. All Rights Reserved by MedPath